We target the translational engine of cancer

tRNA biology sits at the core of cancer adaptation: by rewiring tRNA-dependent translation, tumors rapidly reshape their proteome to survive therapy, evolve resistance, and evade immune control.

Powered by EpiFind, Theratrame is building a new paradigm in oncology by targeting this translational engine at its source.

Our innovation is enabled by a differentiated dual mechanism

  • Adaptive-blocking cytotoxicity, selectively eliminating highly plastic, resistance-prone cancer cells.
  • Tumor-specific immune priming, enabling immune activation even in immune-cold tumors.

EpiFind: THERAtRAME's Proprietary Platform for tRNA-Centric Drug Discovery and Development

Discover

Proprietary tRNA-centric screening / Unique translation biology datasets

Our discovery platform combines in silico approaches with proprietary biochemical assays to identify novel tRNA epitranscriptomic targets. By integrating codon computational modeling and targeted biochemical validation, we guide the rational design of first-in-class inhibitors of tRNA-modifying enzymes involved in adaptive translation in cancer.

Validate

Organoid & in vivio plasticity models / Rapide target-to-lead translation

Drug validation combines proprietary tRNA-focused cellular assays with advanced organoid and murine models to capture tumor-relevant biology. By integrating mechanistic readouts with physiologically relevant systems, we assess target dependency and its impact on tumor cell survival and immune modulation across diverse oncogenic contexts.

Deploy

AI-enabled patient positioning / Multi-indication expansion

Our deployment strategy integrates proprietary AI-driven signatures with patient-derived profiling databases to link target biology to clinically relevant populations. By combining molecular features, biomarker profiles, and translational datasets, we enable precise patient stratification and indication selection. This approach ensures optimal clinical positioning of each asset, maximizing probability of success and therapeutic impact.